Prolonged local expression of anti-CD4 antibody by adenovirally transduced allografts can promote long-term graft survival

Journal of Gene Medicine

Volumn 8, Issue 1, 2006, Pages 42-52

  Londrigan, Sarah L ^a   Sutherland, Robyn M ^a   Brady, Jamie L ^a   Zhan, Yifan ^a   Li, Ruili ^a   Estella, Eugene ^b   Kay, Thomas W H ^b   Lew, Andrew M ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b St Vincent's Public Hospital   (Australia)

Author keywords

Adenovirus; Anti CD4 antibody; Diabetes; Gene transfer; Islet transplant; Local immunosuppression

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIBODY; CD4 ANTIGEN; CELL ANTIBODY; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE TRANSFER; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; KIDNEY CAPSULE; LONG TERM CARE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE SUBPOPULATION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GRAFT SURVIVAL; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; TRANSDUCTION, GENETIC; TRANSPLANTATION, HOMOLOGOUS;

ADENOVIRIDAE; ANIMALIA;

EID: 31644439688     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.818     Document Type: Article

References (51)

1. Sims TW, Good EW. The next generation of medications for kidney transplant patients. Crit Care Nurs Clin North Am 2002; 14: 99-109.
2. Vincenti F. A decade of progress in kidney transplantation. Transplantation 2004; 77: S52-61.
3. Tomasoni S, Benigni A. The goal of intragraft gene therapy. Contrib Nephrol 2005; 146: 143-150.
4. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
5. Hirshberg B, Rother KI, Harlan DM. Islet transplantation: where do we stand now? Diabetes Metab Res Rev 2003; 19: 175-178; discussion 175.
6. Csete ME, Benhamou PY, Drazan KE, et al. Efficient gene transfer to pancreatic islets mediated by adenoviral vectors. Transplantation 1995; 59: 263-268.
7. Grey ST, Arvelo MB, Hasenkamp WM, et al. Adenovirus-mediated gene transfer of the anti-apoptotic protein A20 in rodent islets inhibits IL-1 beta-induced NO release. Transplant Proc 1999; 31: 789.
8. Laumonier T, Potiron N, Boeffard F, et al. CTLA41g adenoviral gene transfer induces long-term islet rat allograft survival, without tolerance, after systemic but not local intragraft expression. Hum Gene Ther 2003; 14: 561-575.
9. Sigalla J, David A, Anegon I, et al. Adenovirus-mediated gene transfer into isolated mouse adult pancreatic islets: normal betacell function despite induction of an anti-adenovirus immune response. Hum Gene Ther 1997; 8: 1625-1634.
10. Thummala NR, Ghosh SS, Lee SW, et al. A non-immunogenic adenoviral vector, coexpressing CTLA41g and bilirubin-uridine-diphosphoglucuronateglucuronosyltransferase, permits longterm, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome. Gene Ther 2002; 9: 981-990.
11. Yasuda H, Nagata M, Arisawa K, et al. Local expression of immunoregulatory IL-12p4O gene prolonged syngeneic islet graft survival in diabetic NOD mice. J Clin Invest 1998; 102: 1807-1814.
12. Shizuru JA, Seydel KB, Flavin TF, et al. Induction of donor-specific unresponsiveness to cardiac allografts in rats by pretransplant anti-CD4 monoclonal antibody therapy. Transplantation 1990; 50: 366-373.
13. Simeonovic CJ, Ceredig R, Wilson JD. Effect of GK1.5 monoclonal antibody dosage on survival of pig proislet xenografts in CD4+ T cell-depleted mice. Transplantation 1990; 49: 849-856.
14. Darby CR, MorTis PJ, Wood KJ. Evidence that long-term cardiac allograft survival induced by anti-CD4 monoclonal antibody does not require depletion of CD4+ T cells. Transplantation 1992; 54: 483-490.
15. Akita K, Ogawa M, Mandel TE. Effect of FK506 and anti-CD4 therapy on fetal pig pancreas xenografts and host lymphoid cells in nod/Lt, CBA, and BALB/c mice. Cell Transplant 1994; 3: 61-73.
16. Mandel TE, Dillon H, Koulmanda M. The effect of a depleting anti-CD4 monoclonal antibody on T cells and fetal pig islet xenograft survival in various strains of mice. Transpl Immunol 1995; 3: 265-272.
17. Wallgren AC, Karlsson-Parra A, Korsgren O. The main infiltrating cell in xenograft rejection is a CD4+ macrophage and not a T lymphocyte. Transplantation 1995; 60: 594-601.
18. He G, Hart J, Kim OS, et al. The role of CD8 and CD4 T cells in intestinal allograft rejection: a comparison of monoclonal antibody-treated and knockout mice. Transplantation 1999; 67: 131-137.
19. Delmonico FL, Cosimi AB. Anti-CD4 monoclonal antibody therapy. Clin Transplant 1996; 10: 397-403.
20. Schulze-Koops H, Lipsky PE. Anti-CD4 monoclonal antibody therapy in human autoimmune diseases. Curr Dir Autoimmunol 2000; 2: 24-49.
21. Boyle JS, Koniaras C, Lew AM. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol 1997; 9: 1897-1906.
22. Liu M, Shapiro ME. A new method for isolation of murine islets with markedly improved yields. Transplant Proc 1995; 27:3208-3210.
23. Sutherland RM, Mountford JN, Allison J, et al. The non-immune RIP-Kb mouse is a useful host for islet transplantation, as the diabetes is spontaneous, mild and predictable. Int J Exp Diabetes Res 2002; 3: 37-45.
24. Zhan Y, Martin RM, Sutherland RM, et al. Local production of anti-CD4 antibody by transgenic allogeneic grafts affords partial protection. Transplantation 2000; 70: 947-954.
25. Zhan Y, Brady JL, Irawaty W, et al. Activated macrophages require T cells for xenograft rejection under the kidney capsule. Immunol Cell Biol 2003; 81: 451-458.
26. Han WR, Zhan Y, Murray-Segal LJ, et al. Prolonged allograft survival in anti-CD4 antibody transgenic mice: lack of residual helper T cells compared with other CD4-deficient mice. Transplantation 2000; 70: 168-174.
27. Vieira P, Rajewsky K. The half-lives of serum immunoglobulins in adult mice. Eur J Immunol 1988; 18: 313-316.
28. Woodcock J, Wofsy D, Eriksson E, et al. Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells. Transplantation 1986; 42: 636-642.
29. Li M, Davey GM, Sutherland RM, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001; 166: 6099-6103.
30. Moriyoshi K, Richards LJ, Akazawa C, et al. Labeling neural cells using adenoviral gene transfer of membrane-targeted GFP. Neuron 1996; 16: 255-260.
31. Mihara M, Tan I, Chuzhin Y, et al. CTLA41g inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000; 106: 91-101.
32. Zsengeller ZK, Wert SE, Hull WM, et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther 1995; 6: 457-467.
33. Scaria A, St George JA, Gregory RJ, et al. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther 1997; 4: 611-617.
34. Kaplan JM, Smith AE. Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum Gene Ther 1997; 8: 1095-1104.
35. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004; 11 (Suppl 1): S 10-17.
36. Guerette B, Vilquin JT, Gingras M, et al. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA41g. Hum Gene Ther 1996; 7: 1455-1463.
37. Kolls JK, Lei D, Odom G, et al. Use of transient CD4 lymphocyte depletion to prolong transgene expression of El-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 489-497.
38. Shean MK, Baskin G, Sullivan D, et al. Immunomodulation and adenoviral gene transfer to the lungs of nonhuman primates. Hum Gene Ther 2000; 11: 1047-1055.
39. Nomura M, Yamashita K, Murakami M, et al. Induction of donor-specific tolerance by adenovirus-mediated CD40Ig gene therapy in rat liver transplantation. Transplantation 2002; 73: 1403-1410.
40. Ehrhardt A, Xu H, Kay MA. Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J Virol 2003;77:7689-7695.
41. Leibowitz G, Beattie GM, Kafri T, et al. Gene transfer to human pancreatic endocrine cells using viral vectors. Diabetes 1999; 48: 745-753.
42. Ayuso E, Chillon M, Agudo J, et al. In vivo gene transfer to pancreatic beta cells by systemic delivery of adenoviral vectors. Hum Gene Ther 2004; 15: 805-812.
43. McKenzie AW, Brady JL, Martin RM, et al. Local secretion of a chimeric anti-CD4 antibody protects against graft rejection in the NOD mouse. Transplantation 2000; 69: 1745-1748.
44. Simeonovic CJ, Brown DJ, Townsend MJ, et al. Differences in the contribution of CD4+ T cells to proislet and islet allograft rejection correlate with constitutive class II MHC alloantigen expression. Cell Transplant 1996; 5: 525-541.
45. Makhlouf L, Yamada A, Ito T, et al. Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. J Am Soc Nephrol 2003; 14: 2168-2175.
46. Zhan Y, Corbett AJ, Brady JL, et al. CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation. J Immunol 2000; 165: 3612-3619.
47. Sutherland RM, Brady JL, Georgiou HM, et al. Protective effect of CTLA41g secreted by transgenic fetal pancreas allografts. Transplantation 2000; 69: 1806-1812.
48. Muruve DA, Manfro RC, Strom TB, et al. Ex vivo adenovirus-mediated gene delivery leads to long-term expression in pancreatic islet transplants. Transplantation 1997; 64: 542-546.
49. Muruve DA, Barnes MJ, Stillman IE, et al. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-976.
50. Worgall S, Wolff G, Falck-Pedersen E, et al. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44.
51. Molinier-Frenkel V, Lengagne R, Gaden F, et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 2002; 76: 127-135.